In January 2017 the FDA approved the first generic sodium oxybate product for narcolepsy symptoms, which is also subject to the same REMS program conditions as the original. By April 2017 7 companies had filed ANDAs with the FDA to market generic versions of Xyrem and Jazz had filed patent infringement cases against them. Hikma Pharmaceuticals had been the first company to file an ANDA and Jazz settled with them in April 2017; under the agreement Hikma could begin selling an authorized generic in 2023 under Jazz' REMS, and would have five years of exclusivity, however, those conditions could change if Jazz' patents were invalidated.